Supriya Lifescience · NSE: SUPRIYA · BSE: 543434
Q1 FY23 results · Apr–Jun 2022
Supriya Lifescience reported revenue from operations of ₹101.36 crore and net profit of ₹25.25 crore for Q1 FY23 (Apr–Jun 2022), on a standalone basis.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 101.36 | — | — | 181.27 | −44.1% |
| Other income | 2.36 | — | — | 3.85 | −38.9% |
| Total income | 103.71 | — | — | 185.12 | −44.0% |
| Profit before tax | 30.14 | — | — | 75.48 | −60.1% |
| Net profit for the period | 25.25 | — | — | 46.21 | −45.4% |
| EPS, basic (₹) | 3.14 | — | — | 5.74 | −45.3% |
| Net margin (%) | 24.9 | — | 25.5 |
Standalone
- Filed with BSE
- 06 Sep 2022, 15:21 IST
- Board meeting
- 12 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE